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PCLINICAL RESEARCH Coronary Artery Disease
Effect of Diabetes on Progression
of Coronary Atherosclerosis and Arterial Remodeling
A Pooled Analysis of 5 Intravascular Ultrasound Trials
Stephen J. Nicholls, MBBS, PHD,*† E. Murat Tuzcu, MD,* Srinivasa Kalidindi, MD, MPH,*
Kathy Wolski, MPH,* Keon-W Moon, MD,* Ilke Sipahi, MD,* Paul Schoenhagen, MD,*
Steven E. Nissen, MD*
Cleveland, Ohio
Objectives Our goal was to characterize coronary atherosclerosis progression and arterial remodeling in diabetic patients.
Background The mechanisms that underlie adverse cardiovascular outcomes in diabetic patients have not been well characterized.
Methods A systematic analysis was performed in 2,237 subjects in randomized controlled studies of atherosclerosis pro-
gression. The pattern of arterial remodeling, extent of coronary atherosclerosis, and disease progression was
compared in subjects with and without diabetes.
Results In association with more risk factors, diabetic patients demonstrated a greater percent atheroma volume (PAV)
(40.2  0.9% vs. 37.5  0.8%, p  0.0001) and total atheroma volume (TAV) (199.4  7.9 mm3 vs. 189.4 
7.1 mm3, p  0.03) on multivariate analysis. A stronger correlation was observed between PAV and glycated
hemoglobin (r  0.22, p  0.0003) than fasting glucose (r  0.09, p  0.0001), although the difference just
failed to meet statistical significance after controlling for study. Diabetic patients exhibited a smaller lumen
(291.1  104.8 mm3 vs. 306.5  108.2 mm3, p  0.005) but no difference in external elastic membrane
(494.9  166.9 mm3 vs. 498.8  167.2 mm3, p  0.61) volumes. More rapid progression of PAV (0.6  0.4%
vs. 0.05  0.3%, p  0.0001) and TAV (0.6  2.5 mm3 vs. 2.7  2.4 mm3, p  0.03) was observed in dia-
betic patients on multivariate analysis. Smaller external elastic membrane (482.5  160.7 mm3 vs. 519.9 
166.9 mm3, p  0.03) and lumen (276.0  100.3 mm3 vs. 310.1  105.6 mm3, p  0.001) volumes were
observed in diabetic patients treated with insulin despite the presence of a similar TAV (206.5  88.6 mm3 vs.
209.9  90.2 mm3, p  0.84). Intensive low-density lipoprotein cholesterol lowering in patients improved the
rate of plaque progression, but only to the level observed in nondiabetic patients with suboptimal lipid control.
Conclusions Diabetes is accompanied by more extensive atherosclerosis and inadequate compensatory remodeling. Accelerated
plaque progression, despite use of medical therapies, supports the need to develop new antiatherosclerotic strategies
in diabetic patients. (J Am Coll Cardiol 2008;52:255–62) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.051a
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rhe global spread of diabetes mellitus is a major factor
ontributing to the prediction that cardiovascular disease
ill become the leading cause of mortality worldwide by
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020 (1). Patients with diabetes have a markedly increased
ncidence of adverse cardiovascular events (2–6) and less
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Diabetes and Atheroma Progression July 22, 2008:255–62treatment of diabetes is a major
component of strategies designed
to reduce cardiovascular risk.
Elucidating the factors that
promote cardiovascular disease in
diabetes is critical for the devel-
opment of new therapeutic ap-
proaches. The prevalence of hy-
perglycemia, hypertension, and
dyslipidemia, in association with
systemic inflammation and oxi-
dative stress, accelerates the for-
mation and propagation of ath-
erosclerotic plaque (13). This
underlies observations from small
clinical (15–17) and necropsy
(18,19) studies that diabetes is
haracterized by diffuse atherosclerosis, with a predilection
or involvement of distal segments in relatively small vessels.
owever, no systematic assessment of the pattern of coro-
ary atherosclerosis and associated arterial wall remodeling
as been performed in a large cohort of diabetic patients by
maging of the entire thickness of the coronary artery wall.
Intravascular ultrasound (IVUS) permits evaluation of the
nfluence of clinical characteristics on changes in coronary
theroma volume (20,21). More recently, IVUS has been
mployed to assess the impact of medical therapies on the
atural history of plaque progression (22–26). The current
tudy investigated the extent and progression of atheroscle-
osis and associated arterial wall remodeling in a large
umber of diabetic patients with coronary artery disease
ho underwent serial evaluation by IVUS.
ethods
ubject selection. Subjects participated in the REVERSAL
Reversal of Atherosclerosis with Aggressive Lipid Lower-
ng) (22), CAMELOT (Comparison of Amlodipine ver-
us Enalapril to Limit Occurrences of Thrombosis) (23),
CTIVATE (Acyl:Cholesterol Acyltransferase Intravas-
ular Atherosclerosis Treatment Evaluation) (24), AS-
EROID (A Study to Evaluate the Effect of Rosuvastatin
n Intravascular Ultrasound-Derived Coronary Atheroma
urden) (25), and ILLUSTRATE (Investigation of Lipid
evel Management Using Coronary Ultrasound to Assess
eduction of Atherosclerosis by Cholesteryl Ester Transfer
rotein Inhibition and High-Density Lipoprotein Eleva-
ion) (26) studies. These were clinical trials that employed
erial IVUS examination to assess the impact of intensive
ipid lowering, antihypertensive therapy, experimental acyl:
holesterol acyltransferase inhibition, or cholesterol ester trans-
er protein inhibition on the progression of coronary athero-
clerosis. All patients were required to have coronary artery
isease, defined as having at least 1 lumen narrowing20% in
major epicardial coronary artery on a diagnostic coronary
Abbreviations
and Acronyms
CRP  C-reactive protein
EEM  external elastic
membrane
HDL  high-density
lipoprotein
IVUS  intravascular
ultrasound
LDL  low-density
lipoprotein
PAV  percent atheroma
volume
TAV  total atheroma
volumengiogram performed for a clinical indication. vcquisition and analysis of IVUS images. The acquisi-
ion and analysis of ultrasonic images have been described in
etail previously (22–26). In brief, after anticoagulation and
dministration of intracoronary nitroglycerin, an imaging
atheter containing a high-frequency ultrasound transducer
30 to 40 MHz) was inserted as far as distally possible
ithin a coronary artery. The target vessel for imaging was
equired to have a segment of at least 30 mm in length that
ontained no lumen narrowing 50%, had not undergone
revious revascularization, and was not considered to be the
ulprit vessel for a prior myocardial infarction. Continuous
ltrasonic imaging was acquired during withdrawal of the
atheter through the segment of artery at a constant rate of
.5 mm/s. Images were stored on videotape and subse-
uently digitized for analysis in a single core laboratory by
ndividuals who were blinded to the clinical characteristics
nd treatment status of the patients.
Matching arterial segments were defined from the images
cquired at the baseline and follow-up studies on the basis
f the anatomic location of proximal and distal side
ranches (fiduciary points). Images spaced precisely 1 mm
part in the segment of interest were selected for analysis.
he leading edge of the lumen and the external elastic
embrane (EEM) were defined by manual planimetry. The
laque area was defined as the difference in area occupied by
he lumen and EEM borders. The total atheroma volume
TAV) was calculated by summation of the plaque area
alculated for each measured image and subsequently nor-
alized to account for differences in segment length be-
ween subjects:
TAVNormalized 
 (EEMareaLumenarea)
number of images in pullback
median number of images in cohort
he percent atheroma volume (PAV) was also calculated by
etermination of the proportion of vessel wall volume
ccupied by atherosclerotic plaque:
PAV 
 (EEMareaLumenarea)
 (EEMarea)
 100
olumes occupied by the lumen and EEM were similarly
alculated by summation of their respective areas in each
easured image and subsequently normalized to account for
ifferences in segment length between subjects.
tatistical analysis. All analyses were performed using
AS version 8.2 (SAS Institute, Cary, North Carolina).
esults are expressed as mean  SD for continuous vari-
bles and percentage for categorical variables. Continuous
ariables that are not normally distributed (triglycerides,
-reactive protein [CRP]) are expressed as median (inter-
uartile range). Comparisons between diabetic and nondi-
betic groups were performed using a random effects model
o account for any potential differences between each indi-
idual study that was pooled for the current analysis (Co-
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July 22, 2008:255–62 Diabetes and Atheroma Progressionhrane’s Q statistic 8.9, p  0.06 and I2  55%, indicating
oderate heterogeneity). Changes in atheroma burden were
xpressed as the least square mean  SEM after controlling
or baseline values. The relationships between biochemical
arameters and measures of atheroma burden and between
hanges in vessel dimensions were determined by calcula-
ion of the Pearson correlation coefficient. A p value 0.05
as considered statistically significant.
esults
linical characteristics. Clinical characteristics are sum-
arized in Table 1. Diabetic subjects were more likely to be
omen (32.7% vs. 26.3%, p 0.008) and African American
7.9% vs. 4.0%, p  0.001), had a greater body mass index
32.4  6.3 kg/m2 vs. 29.7  5.2 kg/m2, p  0.001), and
ad a greater prevalence of hypertension (87.5% vs. 72.2%,
 0.001) and hyperlipidemia (74.3% vs. 67.1%, p 
.004). Subjects with diabetes were more likely to meet the
riteria for the metabolic syndrome (77.1% vs. 41.2%, p 
.001). Diabetic subjects were more likely to have under-
one a previous percutaneous coronary intervention (52.7%
s. 43.2%, p  0.001), were more likely to be treated with
n angiotensin-converting enzyme inhibitor (65.1% vs.
7.6%, p  0.001), and were less likely to receive aspirin
91.8% vs. 94.8%, p  0.02). Among diabetic subjects,
7.0% were treated with insulin and 69.5% received an oral
ypoglycemic agent.
Risk factor control at baseline and follow-up are summa-
ized in Table 2. Predictably, diabetic subjects had higher
evels of fasting plasma glucose (148.4 60.3 mg/dl vs. 96.0
16.9 mg/dl, p  0.001) and glycated hemoglobin (7.4 
.4% vs. 5.7  0.6%, p  0.001). Diabetic subjects had
ower levels of low-density lipoprotein (LDL) cholesterol
102.7  38.2 mg/dl vs. 110.9  38.0 mg/dl, p  0.001)
nd high-density lipoprotein (HDL) cholesterol (41.4 
linical Characteristics and Use of Establishededical T er pi s in Patients With andthout Di betes
Table 1
Clinical Characteristics and Use of Established
Medical Therapies in Patients With and
Without Diabetes
Parameter
Nondiabetic Patients
(n  1,821)
Diabetic Patients
(n  416) p Value
Age (yrs) 57.2 9.5 58.1 9.3 0.06
Women (%) 26.3 32.7 0.008
African Americans (%) 4.0 7.9 0.001
Body mass index (kg/m2) 29.7 5.2 32.4 6.3 0.001
Hypertension (%) 72.2 87.5 0.001
Hyperlipidemia (%) 67.1 74.3 0.004
Metabolic syndrome (%) 41.2 77.1 0.001
Previous MI (%) 30.8 28.4 0.33
Previous CABG (%) 3.8 4.6 0.46
Previous PCI (%) 43.2 52.7 0.001
Statin use (%) 97.9 97.4 0.53
Beta-blocker use (%) 76.3 77.4 0.63
ACE inhibitor use (%) 47.6 65.1 0.001
Aspirin use (%) 94.8 91.8 0.02g
CE  angiotensin-converting enzyme; CABG  coronary artery bypass grafting; MI  myocardial
nfarction; PCI  percutaneous coronary intervention.0.3 mg/dl vs. 44.0  11.8 mg/dl, p  0.001) and higher
evels of triglycerides (159.3 mg/dl vs. 139.0 mg/dl, p 
.001), CRP (2.8 mg/l vs. 2.2 mg/l, p 0.006), and systolic
lood pressure (129.6  17.1 mm Hg vs. 126.1  16.0 mm
g, p 0.001) at baseline. During the course of the studies,
he observed rise in HDL cholesterol was less in diabetic
ubjects (12.5  24.5% vs. 17.0  28.2%, p  0.01).
theroma burden and vessel dimensions. Indexes of
theroma burden and vessel dimensions at baseline are
ummarized in Table 3. The PAV (40.7  9.9% vs. 38.1 
.3%, p 0.001) and TAV (203.8 90.4 mm3 vs. 192.3
4.1 mm3, p  0.03) were greater in diabetic subjects,
onsistent with the presence of more extensive atheroscle-
osis. Multivariate analysis controlling for differences in risk
actors revealed that the presence of diabetes was an inde-
endent predictor of both PAV (p  0.0001) and TAV (p
0.03). A closer correlation was observed with glycated
emoglobin, compared with fasting glucose, and both PAV
r  0.22, p  0.0003 vs. r  0.09, p  0.0001) and TAV
r  0.18, p  0.002 vs. r  0.05, p  0.02), with the
ifference between these markers of glycemic control reach-
ng statistical significance for both measures of plaque
urden (p  0.04). When controlling for study, differences
n correlation between glycated hemoglobin (n  280) and
asting glucose (n  2,216) for both PAV (r  0.19 vs. r 
.09) and TAV (r  0.15 vs. r  0.04) just failed to meet
tatistical significance (p  0.10). Of interest, diabetic
ubjects did not demonstrate more diffuse disease, as evi-
enced by a similar percentage of images containing plaque
76.0  27.7% vs. 73.8  27.5%, p  0.15) as observed in
ondiabetic subjects.
Differences in vascular dimensions were also observed
etween the groups. Despite the presence of more extensive
therosclerosis, lumen volume was smaller in diabetic sub-
ects (291.1  104.8 mm3 vs. 306.5  108.2 mm3, p 
.005), while there was no difference in EEM volume
494.9 166.9 mm3 vs. 498.8 167.2 mm3 in diabetic and
ondiabetic subjects, respectively, p  0.61).
erial changes in atheroma burden and vessel dimensions.
hanges in atheroma burden and vascular dimensions
uring serial evaluation are summarized in Table 4.
reater progression of PAV was observed in diabetic
ubjects (0.8  3.4% vs. 0.3  3.3%, p  0.003).
iabetic subjects were also more likely to undergo
ubstantial atheroma progression (5% relative increase
n PAV, 30.3% vs. 23.2%, p  0.002) and less likely to
ndergo substantial atheroma regression (5% relative
ecrease in PAV, 15.9% vs. 20.3%, p  0.04). Multivar-
ate analysis revealed that the presence of diabetes was an
ndependent predictor of progression of both PAV (p 
.0001) and TAV (p  0.03). A closer relationship was
bserved between baseline levels of glycated hemoglobin
n  280), compared with fasting glucose (n  2,216),
ith changes in TAV (r  0.14, p  0.02 vs. r  0.02,
 0.29), with the difference between these markers oflycemic control reaching statistical significance (p 
0
c
g
w
w
v
a
v
p
n
w-densi
258 Nicholls et al. JACC Vol. 52, No. 4, 2008
Diabetes and Atheroma Progression July 22, 2008:255–62.02). When controlling for study, the difference in
orrelation between glycated hemoglobin and fasting
lucose for the change in TAV (r  0.04 vs. r  0.02)
as not significant (p  0.72). No significant differences
ere observed between groups with regard to changes in
Risk Factor Control at Baseline and Follow-Up aPercentage hange in P ti nts With and Withou
Table 2 Risk Factor Control at Baseline andPercentage Change in Patients Wit
Parameter
Nondiabetic P
(n  1,8
Glucose (mg/dl)
Baseline 96.0 1
Follow-up 101.9 2
Percent change 8.0 2
Total cholesterol (mg/dl)
Baseline 186.6 4
Follow-up 164.2 3
Percent change 8.4 2
LDL cholesterol (mg/dl)
Baseline 110.9 3
Follow-up 83.9 2
Percent change 17.8 2
HDL cholesterol (mg/dl)
Baseline 44.0 1
Follow-up 51.1 1
Percent change 17.0 2
Triglycerides (mg/dl)*
Baseline 139.0 (97.4 to
Follow-up 126.1 (93.4 to
Percent change 8.1 (25.4
CRP (mg/l)*
Baseline 2.2 (1.0 to
Follow-up 1.9 (1.0 to 4
Percent change 14.3 (50.0
Systolic blood pressure (mm Hg)
Baseline 126.1 1
Follow-up 127.6 1
Percent change 2.1 1
Diastolic blood pressure (mm Hg)
Baseline 75.6 9
Follow-up 76.3 7
Percent change 1.9 1
*Median (interquartile range).
CRP  C-reactive protein; HDL  high-density lipoprotein; LDL  lo
Measures of Atheroma Burden and VesselDimensions at Baseline in Patients With and Wi
Table 3 Measures of Atheroma Burden andDimensions at Baseline in Patients
Parameter
Percent atheroma volume
Adjusted percent atheroma volume*
Total atheroma volume (mm3)*
Adjusted total atheroma volume (mm3)
Atheroma volume most diseased 10-mm segment (mm3)
Atheroma volume least diseased 10-mm segment (mm3)
Percentage of images containing plaque
External elastic membrane volume (mm3)
Lumen volume (mm3)*Adjusted for differences in clinical characteristics expressed as least squareascular dimensions. Changes in atheroma volume were
ccompanied by changes in EEM (r  0.58, p  0.0001
s. r  0.62, p  0.0001) but not lumen (r  0.02,
 0.72 vs. r  0.06, p  0.008) in both diabetic and
ondiabetic subjects, respectively.
eirbetes
ow-Up and Their
Without Diabetes
s Diabetic Patients
(n  416) p Value
148.4 60.3 0.001
154.0 64.3 0.001
12.7 50.5 0.43
181.1 46.4 0.008
160.5 33.2 0.02
7.9 21.4 0.84
102.7 38.2 0.001
80.4 24.9 0.01
14.2 31.2 0.06
41.4 10.3 0.001
46.3 15.2 0.001
12.5 24.5 0.01
) 159.3 (111.5 to 236.0) 0.001
) 142.0 (103.3 to 206.7) 0.001
7) 7.9 (23.9 to 12.4) 0.87
2.8 (1.2 to 6.1) 0.006
2.3 (1.0 to 5.9) 0.001
9) 8.6 (47.4 to 58.7) 0.08
129.6 17.1 0.001
130.1 14.6 0.001
1.2 10.8 0.29
75.3 9.5 0.51
75.1 7.9 0.002
0.6 11.9 0.05
ty lipoprotein.
t Diabetes
el
and Without Diabetes
ndiabetic Patients
(n  1,821)
Diabetic Patients
(n  416) p Value
38.1 9.3 40.7 9.9 0.001
37.5 0.8 40.2 0.9 0.0001
192.3 84.1 203.8 90.4 0.03
189.4 7.1 199.4 7.9 0.03
62.3 28.8 65.4 30.6 0.06
43.0 25.9 45.4 27.1 0.12
73.8 27.5 76.0 27.7 0.15
498.8 167.2 494.9 166.9 0.61
306.5 108.2 291.1 104.8 0.005nd Tht Dia
Foll
h and
atient
21)
6.9
4.0
6.7
4.5
1.6
1.9
8.0
5.4
9.6
1.8
7.5
8.2
195.0
170.4
to 13.
4.5)
.0)
to 42.
6.0
3.2
1.2
.1
.4
1.6thou
Vess
With
Nod mean  SEM.
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July 22, 2008:255–62 Diabetes and Atheroma Progressionnsulin therapy, atheroma burden, and arterial remodel-
ng. Vascular dimensions and atheroma burden were fur-
her explored in diabetic subjects, classified according to use
f insulin. Patients receiving insulin demonstrated smaller
EM (482.5  160.7 mm3 vs. 519.9  166.9 mm3, p 
.03) and lumen (276.0  100.3 mm3 vs. 310.1  105.6
m3, p  0.001) volumes. This resulted in a larger PAV
42.4  10.2% vs. 39.9  9.6%, p  0.02) despite the
resence of a similar TAV (206.5  88.6 mm3 vs. 209.9 
0.2 mm3, p  0.84). This observation suggests that the
emodeling pattern may differ in insulin-treated patients.
n serial evaluation, no differences were observed in
hanges in PAV (0.9  3.4% vs. 0.8  3.4%, p  0.54) and
AV (1.6  21.9 mm3 vs. 1.2  25.7 mm3, p  0.34)
Changes in Measures of Atheroma Burdenand Vessel Dimensions in Patients With and Wi
Table 4 Changes in Measures of Atheromaand Vessel Dimensions in Patients
Parameter
N
Percent atheroma volume
Adjusted percent atheroma volume*
Total atheroma volume (mm3)
Adjusted total atheroma volume (mm3)*
Atheroma volume most diseased segment (mm3)
Atheroma volume least diseased segment (mm3)
Substantial regressors (%)
Substantial progressors (%)
External elastic membrane volume (mm3)
Lumen volume (mm3)
*Adjusted for differences in clinical characteristics and baseline ather
Figure 1 LDL Lowering and Plaque Progression
Changes in percent atheroma volume (PAV) (top left) and total atheroma volume (
5% relative decrease in PAV, bottom left) and progression (at least 5% relative inc
mellitus (DM) stratified according to a level of low-density lipoprotein cholesterol (Ln diabetic patients treated with and without insulin, respec-
ively. Diabetic patients treated with and without insulin
lso demonstrated similar changes in EEM (13.4  4.9
m3 vs.15.5 4.8 mm3, p 0.58) and lumen (10.7
.0 mm3 vs. 12.6 mm3, p  0.55) volumes.
ntensive lowering of LDL cholesterol and CRP and
theroma progression. The impact of intensive lowering
f levels of LDL cholesterol below 80 mg/dl on progression
f coronary atherosclerosis is summarized in Figure 1.
ntensive lowering of LDL cholesterol had a beneficial
mpact on progression of PAV in both diabetic (0.4  3.2%
s. 1.3  3.6%, p  0.008) and nondiabetic (0.2  3.0%
s. 0.6  3.5%, p  0.001) subjects and on progression of
AV in diabetic subjects (5.0  21.7 mm3 vs. 2.2  24.8
Diabetes
n
and Without Diabetes
betic Patients
 1,821)
Diabetic Patients
(n  416) p Value
0.3 3.3 0.8 3.4 0.003
.05 0.3 0.6 0.4 0.0001
4.0 21.8 1.8 23.3 0.15
2.7 2.4 0.6 2.5 0.03
3.5 10.6 2.6 10.4 0.13
0.1 7.9 0.5 8.3 0.42
20.3 15.9 0.04
23.2 30.3 0.002
3.2 38.4 13.0 39.5 0.97
9.2 30.2 11.2 32.3 0.14
rden, expressed as least squared mean  SEM.
top right) and proportion of subjects undergoing substantial regression (at least
in percent atheroma volume, bottom right) in patients with and without diabetes
 or 80 mg/dl with treatment. LDL  low-density lipoprotein.thout
Burde
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Diabetes and Atheroma Progression July 22, 2008:255–62m3, p  0.001) and nondiabetic subjects (6.9  19.5
m3 vs. 1.5  23.3 mm3, p  0.001). Intensive lowering
f LDL cholesterol also resulted in a greater proportion of
ubjects undergoing substantial regression (at least 5%
elative reduction in PAV) in diabetic subjects (18.5% vs.
3.0%, p  0.12) and nondiabetic subjects (23.4% vs.
7.5%, p  0.002). The proportion of subjects undergoing
ubstantial progression (at least 5% relative increase in
AV) was reduced with intensive lowering of LDL choles-
erol in both diabetic subjects (26.9% vs. 35.2%, p  0.07)
nd nondiabetic subjects (18.4% vs. 27.4%, p  0.001). Of
nterest, intensive lowering of LDL cholesterol only im-
roved progression rates of diabetic subjects to that observed
n the nondiabetic subject without intensive control of LDL
holesterol. The impact of intensive lowering of CRP was
nvestigated in subjects in whom CRP measurements were
vailable (n  1,727). While a similar trend was observed
ith regard to achieving a CRP level 2 mg/l, none of the
omparisons achieved statistical significance (Fig. 2).
iscussion
n recent years, IVUS has been increasingly used to study
he progression of coronary atherosclerosis and the impact
f pharmacological therapies on the arterial wall (22–26).
iven that each of these clinical trials has included patients
ith diabetes, a pooled analysis of the studies enables a
ystematic assessment of the differences in the pattern of
therosclerosis in diabetic patients compared with that in
Figure 2 CRP Lowering and Plaque Progression
Changes in PAV (top left) and TAV (top right) and proportion of subjects undergoi
bottom left) and progression (at least 5% relative increase in percent atheroma vo
C-reactive protein (CRP)  or 2 mg/l with treatment. Abbreviations as in Figure 1ondiabetic patients. In the current pooled analysis of 5 trospective clinical trials, the presence of diabetes was
ssociated with a greater atherosclerotic burden and im-
aired compensatory remodeling of the artery wall. Further-
ore, atheroma progression, despite the high use of estab-
ished medical therapies, was more rapid in patients with
iabetes. This highlights the important mechanistic links
hat underscore the aggressive nature of atherosclerotic
ardiovascular disease in patients with diabetes.
The presence of more extensive disease confirms through
irect observations of the vessel wall the finding that
iabetic patients have an accelerated form of atherosclerotic
isease. A number of pathophysiologic abnormalities likely
xplain the more rapid progression of disease. The presence
f diabetes is accompanied by a greater prevalence of
stablished atherosclerotic risk factors including hyperten-
ion; low levels of HDL cholesterol; hypertriglyceridemia;
he presence of small, dense LDL particles; and obesity.
owever, conventional risk factors alone represent only a
ortion of the excess disease burden. Hyperglycemia and the
otential generation of advanced glycation end products also
eem to play an important role (27). The chronic influence
f hyperglycemia is supported by the observation of a
orrelation between measures of atheroma burden and
lycated hemoglobin, a marker of long-term glycemic con-
rol. The presence of elevated systemic markers of inflam-
ation and oxidative stress provide additional mechanisms
hat may contribute to the accelerated form of atherosclerosis.
The current observations also suggest that abnormali-
stantial regression (at least 5% relative decrease in percent atheroma volume,
bottom right) in patients with and without DM stratified according to a level ofng sub
lume,
.ies of arterial remodeling may influence the clinical
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July 22, 2008:255–62 Diabetes and Atheroma Progressionxpression of disease in diabetes. Angiographic studies in
iabetics typically reveal diffuse disease with a predilec-
ion for distal segments of relatively small vessels (28).
he current findings suggest that the pattern of disease in
iabetes is not more diffuse in the patient with angio-
raphic abnormalities. Indeed, the presence of more
xtensive atherosclerosis involving a similar proportion of
mages is consistent with a pattern of disease that may be
ore focal than previously considered. The finding that
umen volumes are smaller in the diabetic subjects is
onsistent with the observation of smaller vessels on
ngiography. A similar EEM volume and smaller lumen,
espite the presence of more extensive atherosclerosis,
uggests that diabetes is accompanied by impaired com-
ensatory remodeling of the arterial wall. The mecha-
isms that promote impaired arterial remodeling in
iabetes remain to be defined. However, it is possible that
ncreasing deposition of fibrous (29,30) and calcific (31)
issue in the arterial wall, in addition to impaired
ndothelial-dependent relaxation (32), may limit vessel
all expansion with plaque accumulation. Given its role
n the promotion of obstructive disease, inadequate arte-
ial remodeling represents an additional target for ther-
peutic modification in diabetic patients with coronary
rtery disease.
Impairment of compensatory remodeling appears to be
rominent in diabetic patients treated with insulin and
upports previous observations in studies of native athero-
clerosis (33,34) and heart transplant recipients (35). These
atients demonstrated smaller vascular dimensions and a
reater PAV, despite the presence of a similar TAV. This
uggests that inadequate compensatory remodeling is par-
icularly evident in the insulin-treated patient. Proliferation
f smooth muscle and fibrous tissue in response to insulin
36) might increase vascular stiffness and further impair the
bility of the artery wall to expand in response to accumu-
ation of plaque.
This study provides insight into the impact of established
edical therapies on atheroma progression in the setting of
iabetes. In previous studies of patients with established
oronary artery disease, lipid-modifying therapies slowed
rogression of obstructive disease by angiography (37). This
s consistent with the observation that the greatest clinical
enefit of medical management of diabetic patients is
erived from optimal control of blood pressure (38) and
ipids (39–41). However, despite the high rate of use of
lood pressure and lipid-modifying therapies, accelerated
isease progression was observed in diabetic patients. Fur-
hermore, while intensive lowering of LDL cholesterol had
favorable impact on plaque progression, the diabetic
ubjects continued to demonstrate greater increases in ath-
roma volume. This residual progression suggests that an
ncremental benefit might be derived from use of emerging
edical therapies, which modify additional targets includ-
ng hyperglycemia and inflammatory mediators of disease in
he arterial wall. The more recent observation that improv-ng control of glycemic, lipid, and inflammatory markers
ith the peroxisome proliferator-activated receptor-gamma
gonist pioglitazone slows progression of carotid intimal-
edial thickness (42) suggests that this strategy may also have
beneficial impact on established coronary atherosclerosis.
tudy limitations. A number of caveats should be noted
ith regard to the current analysis. The results of this
nalysis were obtained by pooling data from a number of
linical trials. The diagnosis of diabetes was recorded on the
asis of the clinical report form of each study. As duration
f diabetes was not recorded, it is unknown whether the
xtent of atherosclerosis and inadequate remodeling was
reater in those subjects with a longer history of impaired
lycemic control. As all patients had a diagnosis of coronary
rtery disease at the time of a clinically indicated angiogram,
t is unknown if the current findings can be translated to the
etting of primary prevention. However, the observation
hat asymptomatic diabetic patients have a prospective
ardiovascular risk comparable to that of nondiabetic survi-
ors of myocardial infarction (14) suggests that the under-
ying disease is aggressive even in the patient who has yet to
ome to clinical attention. As the direct relationship be-
ween the extent of atherosclerosis on IVUS and clinical
utcome continues to be defined, it remains to be deter-
ined to what extent the differences in plaque burden
ontribute to the adverse cardiovascular outcome observed
n diabetic patients with established coronary artery disease.
onclusions
he current analysis of a large number of diabetic subjects
eveals the presence of more extensive atherosclerosis in
ssociation with impaired compensatory remodeling of the
rterial wall. While a benefit on disease progression is
bserved with the use of medical therapies, an accelerated
ncrease in atheroma volume is observed in comparison with
hat seen in patients without diabetes. This finding suggests
hat there is an ongoing need to develop new therapies that
omplement modification of established risk factors to
chieve a greater benefit in halting disease progression in
iabetic patients resulting in optimal reduction of cardio-
ascular risk.
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